Y-mAbs Therapeutics, Inc. Litigation

Jun 24, 2025

Disbursement Approved

The court has approved the distribution of settlement funds to eligible class members. Investors with approved claims may receive payments from the settlement. If you have questions about your claim or payment, contact the claims administrator.

Oct 29, 2024

Final Approval of Settlement

The court has granted final approval of the settlement. Eligible investors who submit valid claims may receive a payment once the claims review and distribution process is completed.

Oct 7, 2024

Motion for Final Approval of Settlement

The parties have asked the court to grant final approval of the proposed settlement. The judge will consider whether the settlement should be approved after reviewing the settlement terms and any objections. If approved, eligible investors who submit valid claims may receive a payment after the claims review and distribution process is completed.

Jul 1, 2024

Preliminary Approval of Settlement

The court has granted preliminary approval of a proposed settlement. This means the settlement can move forward for further consideration, but it has not yet received final approval. Potential class members will generally receive notice explaining the settlement, their rights, and any deadlines for submitting a claim, objecting to the settlement, or choosing not to participate.

Jul 1, 2024

Proposed Settlement

Jul 1, 2024

Proof of Claim Form

To receive your portion of the recovery (if you are eligible), you must submit this form to the claims administrator by the deadline indicated on the form itself. If you do not submit this form in time, you will not be entitled to compensation. If you have questions about how to complete the form, you should contact the claims administrator.

Jun 27, 2024

Motion for Preliminary Approval of Settlement

The parties have asked the court to give preliminary approval to a proposed settlement. The judge will review the request and decide whether the settlement can move forward to the next stage. If approved, potential class members will generally receive information about the settlement and their rights, including any deadlines for taking action.

Feb 5, 2024

Motion to Dismiss Denied in Part

The court has determined that plaintiffs have adequately alleged some of their claims, but have failed to adequately allege other claims. The judge has therefore denied in part the motion to dismiss filed by defendants and written an order stating which claims are dismissed and which remain. The case will proceed and parties will litigate the remaining claims.

Jul 11, 2023

Motion to Dismiss

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

May 23, 2023

First Amended Complaint

A new complaint has been filed on behalf of certain investors in Y-mAbs Therapeutics, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Apr 4, 2023

Appointment of Lead Plaintiff

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Jan 18, 2023

First Filed Complaint

A securities fraud class action complaint has been filed on behalf of certain investors in Y-mAbs Therapeutics, Inc..